Close Menu

Intermountain Healthcare

Consenting participants will have their deidentified sequence data used for research and will also have the chance to learn if they have clinically actionable results.

The partners are both "investing heavily" in the study and will have access to the data and to new technologies and interventions.

The mCODE team recently released standards for inputting genomic and other data into patient records to boost patient record transferability and trial participation.

Before broad implementation, the healthcare system will gauge the feasibility of the screening program, patient impact, and cost-benefit in a pilot phase.

Hospitals and philanthropies in the US are forming their own drug company called Civica Rx.

Researchers can apply to receive $100,000 in matched funds from Intermountain to cover project costs related to high-throughput genomic sequencing.

The partnership has allowed Philips to provide a single view of cancer patient's status, including genomic test results, through the FDA-cleared IntelliSite Pathology Solution.

 

The health system hopes to pair the data with nearly three decades worth of electronic health records as well as medical histories provided by contributors.

Following several Sync for Genes pilots, FHIR Genomics advocates are pushing for adoption of their standard to make omics data compatible with EHRs.

Results from a randomized clinical trial known as GIFT suggest that genotype-guided warfarin dosing is linked to fewer adverse events than clinical dosing.

Pages

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.